A phase II clinical trial of Sargramostim to determine whether it is safe and can help slow or prevent the progression of Alzheimer's in the general population
Latest Information Update: 27 Oct 2021
At a glance
- Drugs Sargramostim (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 27 Oct 2021 New trial record
- 21 Oct 2021 According to a University of Colorado at Anschutz Medical Campus media release, this study received funding form GLOBAL and the Alzheimer's Association of $1 million and the NIH provided another $7.5 million to complete the trial work which may be complete as early as 2026.